Zacks: Brokerages Expect Kura Oncology, Inc. (NASDAQ:KURA) Will Announce Earnings of -$0.52 Per Share

Equities analysts expect that Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) will post ($0.52) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.61). Kura Oncology reported earnings per share of ($0.51) in the same quarter last year, which suggests a negative year-over-year growth rate of 2%. The business is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Kura Oncology will report full year earnings of ($2.19) per share for the current fiscal year, with EPS estimates ranging from ($2.70) to ($1.99). For the next year, analysts anticipate that the company will report earnings of ($2.18) per share, with EPS estimates ranging from ($2.45) to ($1.97). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Kura Oncology.

Kura Oncology (NASDAQ:KURA – Get Rating) last issued its quarterly earnings data on Wednesday, May 4th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.03. During the same period last year, the company posted ($0.46) EPS.

KURA has been the subject of several recent analyst reports. SVB Leerink cut their target price on shares of Kura Oncology from $41.00 to $28.00 and set an “outperform” rating for the company in a research note on Friday, February 25th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. Credit Suisse Group raised their price objective on shares of Kura Oncology from $25.00 to $27.00 and gave the stock an “outperform” rating in a research report on Friday, February 25th. Zacks Investment Research downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, May 5th. Finally, Jefferies Financial Group began coverage on shares of Kura Oncology in a research report on Tuesday, February 15th. They issued a “buy” rating and a $35.00 price target for the company. Two research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $38.00.

Shares of NASDAQ KURA opened at $12.59 on Friday. The stock has a market capitalization of $839.00 million, a price-to-earnings ratio of -6.33 and a beta of 1.39. The business has a 50-day moving average of $14.85 and a 200-day moving average of $14.67. Kura Oncology has a fifty-two week low of $10.41 and a fifty-two week high of $24.36.

A number of large investors have recently made changes to their positions in KURA. Deep Track Capital LP bought a new stake in shares of Kura Oncology during the fourth quarter worth $35,700,000. Invesco Ltd. grew its stake in shares of Kura Oncology by 96.8% during the third quarter. Invesco Ltd. now owns 3,000,140 shares of the company’s stock worth $56,194,000 after buying an additional 1,475,350 shares during the last quarter. Deerfield Management Company L.P. Series C grew its stake in shares of Kura Oncology by 51.8% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 3,513,756 shares of the company’s stock worth $49,193,000 after buying an additional 1,198,339 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Kura Oncology by 222.0% in the first quarter. Assenagon Asset Management S.A. now owns 1,680,196 shares of the company’s stock worth $27,018,000 after purchasing an additional 1,158,356 shares during the last quarter. Finally, Suvretta Capital Management LLC grew its stake in shares of Kura Oncology by 45.2% in the fourth quarter. Suvretta Capital Management LLC now owns 3,572,419 shares of the company’s stock worth $50,014,000 after purchasing an additional 1,112,217 shares during the last quarter. 94.65% of the stock is currently owned by institutional investors and hedge funds.

Kura Oncology Company Profile (Get Rating)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications.

Further Reading